Voyager Therapeutics Stock News

EC, SKX, BVN, VYGR and WU have been added to the Zacks Rank #1 (Strong Buy) List on May 1, 2023.

Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer's disease and

With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.

If soaring consumer prices got you down, you may want to consider these value stocks under $20. Sure, the market may be booming during this unique post-pandemic cycle.

The company's strength lies in its TRACER capsids technology that can deliver therapeutic molecules to the brain, leading to multimillion-dollar deals with pharmaceutical giants, such as Novartis. Des

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcript

While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.

LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fou

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Financi

The financial markets in 2024 will be pulsating with transformative opportunities driven by companies poised to redefine industries. This is leading to several 2024 investment trends making themselves

Voyager Therapeutics Inc. NASDAQ: VYGR is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with Novart

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

Voyager Therapeutics' announcement that it has entered into an additional up to $1.2 billion collaboration with Novartis AG (ADR) (NYSE:NVS) for its TRACER capsids to develop potential gene therapies

Shares of Voyager Therapeutics Inc. (VYGR) jumped Tuesday after the biotech firm agreed to a strategic collaboration and capsid licensing agreement with Novartis AG (NVS) to treat neurological illness